FoxO4 Promotes Early Inflammatory Response Upon Myocardial Infarction via Endothelial Arg1

Circulation Research

Volumn 117, Issue 11, 2015, Pages 967-977

  Zhu, Min ^a   Goetsch, Sean C ^a   Wang, Zhaoning ^a   Luo, Robert ^a   Hill, Joseph A ^a   Schneider, Jay ^a   Morris, Sidney M ^b   Liu, Zhi Ping ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

arginase; endothelial cells; FoxO4 protein, mouse; inflammation; myocardial infarction

Indexed keywords

ARGINASE 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXO4; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ARG1 PROTEIN, MOUSE; ARGINASE; ARGINASE I, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXO4 PROTEIN, HUMAN; FOXO4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL ADHESION; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INDUCTION; ENZYME INHIBITION; GENE DELETION; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MONOCYTE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SURVIVAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CARDIAC MUSCLE CELL; COCULTURE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PATHOPHYSIOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; U-937 CELL LINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARGINASE; BINDING SITES; CELL ADHESION; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENZYME INDUCTION; FORKHEAD TRANSCRIPTION FACTORS; HEK293 CELLS; HUMANS; INFLAMMATION; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; NEUTROPHIL INFILTRATION; NITRIC OXIDE; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; U937 CELLS;

EID: 84946495477     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.306919     Document Type: Article

References (43)

1. Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev. 2011;16:13-21. doi: 10.1007/s10741-010-9181-7.
2. Frangogiannis NG. Inflammation in cardiac injury, repair and regeneration. Curr Opin Cardiol. 2015;30:240-245. doi: 10.1097/ HCO.0000000000000158.
3. Roberts R, DeMello V, Sobel BE. Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation. 1976;53:I204-I206.
4. Christia P, Frangogiannis NG. Targeting inflammatory pathways in myocardial infarction. Eur J Clin Invest. 2013;43:986-995. doi: 10.1111/eci.12118.
5. van den Akker F, Deddens JC, Doevendans PA, Sluijter JP. Cardiac stem cell therapy to modulate inflammation upon myocardial infarction. Biochim Biophys Acta. 2013;1830:2449-2458. doi: 10.1016/j.bbagen.2012.08.026.
6. Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation. 1983;67:1016-1023.
7. Litt MR, Jeremy RW, Weisman HF, Winkelstein JA, Becker LC. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury. Circulation. 1989;80:1816-1827.
8. Palatianos GM, Balentine G, Papadakis EG, Triantafillou CD, Vassili MI, Lidoriki A, Dinopoulos A, Astras GM. Neutrophil depletion reduces myocardial reperfusion morbidity. Ann Thorac Surg. 2004;77:956-961. doi: 10.1016/j.athoracsur.2003.10.004.
9. Eijkelenboom A, Burgering BM. FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol. 2013;14:83-97. doi: 10.1038/nrm3507.
10. Sengupta A, Molkentin JD, Paik JH, DePinho RA, Yutzey KE. FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress. J Biol Chem. 2011;286:7468-7478. doi: 10.1074/jbc. M110.179242.
11. Liu ZP, Wang Z, Yanagisawa H, Olson EN. Phenotypic modulation of smooth muscle cells through interaction of Foxo4 and myocardin. Dev Cell. 2005;9:261-270. doi: 10.1016/j.devcel.2005.05.017.
12. Li H, Liang J, Castrillon DH, DePinho RA, Olson EN, Liu ZP. FoxO4 regulates tumor necrosis factor alpha-directed smooth muscle cell migration by activating matrix metalloproteinase 9 gene transcription. Mol Cell Biol. 2007;27:2676-2686. doi: 10.1128/MCB.01748-06.
13. Zhou W, Cao Q, Peng Y, Zhang QJ, Castrillon DH, DePinho RA, Liu ZP. FoxO4 inhibits NF-kappaB and protects mice against colonic injury and inflammation. Gastroenterology. 2009;137:1403-1414. doi: 10.1053/j. gastro.2009.06.049.
14. Zhu M, Zhang QJ, Wang L, Li H, Liu ZP. FoxO4 inhibits atherosclerosis through its function in bone marrow derived cells. Atherosclerosis. 2011;219:492-498. doi: 10.1016/j.atherosclerosis.2011.09.038.
15. Morris SM Jr. Arginases and arginine deficiency syndromes. Curr Opin Clin Nutr Metab Care. 2012;15:64-70. doi: 10.1097/MCO.0b013e32834d1a08.
16. Morris CR, Gladwin MT, Kato GJ. Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med. 2008;8:620-632.
17. Liao JK. Linking endothelial dysfunction with endothelial cell activation. J Clin Invest. 2013;123:540-541. doi: 10.1172/JCI66843.
18. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 2009;37:W305-W311. doi: 10.1093/nar/gkp427.
19. Rau CD, Wang J, Avetisyan R, Romay MC, Martin L, Ren S, Wang Y, Lusis AJ. Mapping genetic contributions to cardiac pathology induced by beta-adrenergic stimulation in mice. Circ Cardiovasc Genet. 2015;8:40-49. doi: 10.1161/CIRCGENETICS.113.000732.
20. van den Borne SW, van de Schans VA, Strzelecka AE, Vervoort-Peters HT, Lijnen PM, Cleutjens JP, Smits JF, Daemen MJ, Janssen BJ, Blankesteijn WM. Mouse strain determines the outcome of wound healing after myocardial infarction. Cardiovasc Res. 2009;84:273-282. doi: 10.1093/cvr/cvp207.
21. Gitler AD, Kong Y, Choi JK, Zhu Y, Pear WS, Epstein JA. Tie2-Cre-induced inactivation of a conditional mutant Nf1 allele in mouse results in a myeloproliferative disorder that models juvenile myelomonocytic leukemia pediatric research. 2004;55:581-584
22. Moore-Morris T, Guimarães-Camboa N, Banerjee I, et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J Clin Invest. 2014;124:2921-2934. doi: 10.1172/JCI74783.
23. Morris SM Jr. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol. 2009;157:922-930. doi: 10.1111/j.1476-5381.2009.00278.x.
24. Bekpinar S, Gurdol F, Unlucerci Y, Develi S, Yilmaz A. Serum levels of arginase I are associated with left ventricular function after myocardial infarction. Clin Biochem. 2011;44:1090-1093. doi: 10.1016/j. clinbiochem.2011.06.003.
25. Jung C, Gonon AT, Sjöquist PO, Lundberg JO, Pernow J. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res. 2010;85:147-154. doi: 10.1093/cvr/cvp303.
26. Sediri Y, Kallel A, Ben Ali S, Omar S, Mourali MS, Elasmi M, Taieb SH, Sanhaji H, Feki M, Mechmeche R, Jemaa R, Kaabachi N. Association of rs2781666 G/T polymorphism of arginase I gene with myocardial infarction in Tunisian male population. Clin Biochem. 2010;43:106-109. doi: 10.1016/j.clinbiochem.2009.10.058.
27. Schlüter KD, Schulz R, Schreckenberg R. Arginase induction and activation during ischemia and reperfusion and functional consequences for the heart. Front Physiol. 2015;6:65. doi: 10.3389/fphys.2015.00065.
28. Singh M, Padhy G, Vats P, Bhargava K, Sethy NK. Hypobaric hypoxia induced arginase expression limits nitric oxide availability and signaling in rodent heart. Biochim Biophys Acta. 2014;1840:1817-1824. doi: 10.1016/j.bbagen.2014.01.015.
29. Bhatta A, Yao L, Toque HA, Shatanawi A, Xu Z, Caldwell RB, Caldwell RW. Angiotensin II-induced arterial thickening, fibrosis and stiffening involves elevated arginase function. PLoS One. 2015;10:e0121727. doi: 10.1371/journal.pone.0121727.
30. Tratsiakovich Y, Yang J, Gonon AT, Sjöquist PO, Pernow J. Arginase as a target for treatment of myocardial ischemia-reperfusion injury. Eur J Pharmacol. 2013;720:121-123. doi: 10.1016/j.ejphar.2013.10.040.
31. Grönros J, Kiss A, Palmér M, Jung C, Berkowitz D, Pernow J. Arginase inhibition improves coronary microvascular function and reduces infarct size following ischaemia-reperfusion in a rat model. Acta Physiol (Oxf). 2013;208:172-179. doi: 10.1111/apha.12097.
32. Farré D, Roset R, Huerta M, Adsuara JE, Roselló L, Albà MM, Messeguer X. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 2003;31:3651-3653.
33. Shemyakin A, Kövamees O, Rafnsson A, Böhm F, Svenarud P, Settergren M, Jung C, Pernow J. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation. 2012;126:2943-2950. doi: 10.1161/ CIRCULATIONAHA.112.140335.
34. Kövamees O, Shemyakin A, Pernow J. Effect of arginase inhibition on ischemia-reperfusion injury in patients with coronary artery disease with and without diabetes mellitus. PLoS One. 2014;9:e103260. doi: 10.1371/ journal.pone.0103260.
35. Darra E, Rungatscher A, Carcereri de Prati A, Podesser BK, Faggian G, Scarabelli T, Mazzucco A, Hallström S, Suzuki H. Dual modulation of nitric oxide production in the heart during ischaemia/reperfusion injury and inflammation. Thromb Haemost. 2010;104:200-206. doi: 10.1160/ TH09-08-0554.
36. Yang J, Gonon AT, Sjöquist PO, Lundberg JO, Pernow J. Arginase regulates red blood cell nitric oxide synthase and export of cardioprotective nitric oxide bioactivity. Proc Natl Acad Sci U S A. 2013;110:15049-15054. doi: 10.1073/pnas.1307058110.
37. Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T, Michael LH, Rollins BJ, Entman ML, Frangogiannis NG. CCL2/ monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res. 2005;96:881-889. doi: 10.1161/01.RES.0000163017.13772.3a.
38. Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A, Frangogiannis NG. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol. 2008;173:57-67. doi: 10.2353/ajpath.2008.070974.
39. Moelker AD, Baks T, van den Bos EJ, van Geuns RJ, de Feyter PJ, Duncker DJ, van der Giessen WJ. Reduction in infarct size, but no functional improvement after bone marrow cell administration in a porcine model of reperfused myocardial infarction. Eur Heart J. 2006;27:3057-3064. doi: 10.1093/eurheartj/ehl401.
40. Gomis RR, Alarcón C, He W, Wang Q, Seoane J, Lash A, Massagué J. A FoxO-Smad synexpression group in human keratinocytes. Proc Natl Acad Sci U S A. 2006;103:12747-12752. doi: 10.1073/ pnas.0605333103.
41. Pernow J, Jung C. Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? Cardiovasc Res. 2013;98:334-343. doi: 10.1093/cvr/cvt036.
42. Gray MJ, Poljakovic M, Kepka-Lenhart D, Morris SM Jr. Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta. Gene. 2005;353:98-106. doi: 10.1016/j. gene.2005.04.004.
43. Sheldon KE, Shandilya H, Kepka-Lenhart D, Poljakovic M, Ghosh A, Morris SM Jr. Shaping the murine macrophage phenotype: IL-4 and cyclic AMP synergistically activate the arginase I promoter. J Immunol. 2013;191:2290-2298. doi: 10.4049/jimmunol.1202102.